519 related articles for article (PubMed ID: 27980081)
21. HAUS8 regulates RLR‑VISA antiviral signaling positively by targeting VISA.
He TS; Chen T; Wang DD; Xu LG
Mol Med Rep; 2018 Aug; 18(2):2458-2466. PubMed ID: 29916539
[TBL] [Abstract][Full Text] [Related]
22. MAVS activates TBK1 and IKKε through TRAFs in NEMO dependent and independent manner.
Fang R; Jiang Q; Zhou X; Wang C; Guan Y; Tao J; Xi J; Feng JM; Jiang Z
PLoS Pathog; 2017 Nov; 13(11):e1006720. PubMed ID: 29125880
[TBL] [Abstract][Full Text] [Related]
23. The E3 ubiquitin ligase Triad3A negatively regulates the RIG-I/MAVS signaling pathway by targeting TRAF3 for degradation.
Nakhaei P; Mesplede T; Solis M; Sun Q; Zhao T; Yang L; Chuang TH; Ware CF; Lin R; Hiscott J
PLoS Pathog; 2009 Nov; 5(11):e1000650. PubMed ID: 19893624
[TBL] [Abstract][Full Text] [Related]
24. Sendai virus V protein decreases nitric oxide production by inhibiting RIG-I signaling in infected RAW264.7 macrophages.
Morita N; Tanaka Y; Odkhuu E; Naiki Y; Komatsu T; Koide N
Microbes Infect; 2020 Sep; 22(8):322-330. PubMed ID: 32032681
[TBL] [Abstract][Full Text] [Related]
25. The NEMO adaptor bridges the nuclear factor-kappaB and interferon regulatory factor signaling pathways.
Zhao T; Yang L; Sun Q; Arguello M; Ballard DW; Hiscott J; Lin R
Nat Immunol; 2007 Jun; 8(6):592-600. PubMed ID: 17468758
[TBL] [Abstract][Full Text] [Related]
26. MST4 negatively regulates type I interferons production via targeting MAVS-mediated pathway.
Liu W; Ma Z; Wu Y; Yuan C; Zhang Y; Liang Z; Yang Y; Zhang W; Jiao P
Cell Commun Signal; 2022 Jul; 20(1):103. PubMed ID: 35820905
[TBL] [Abstract][Full Text] [Related]
27. The small GTPase RAB1B promotes antiviral innate immunity by interacting with TNF receptor-associated factor 3 (TRAF3).
Beachboard DC; Park M; Vijayan M; Snider DL; Fernando DJ; Williams GD; Stanley S; McFadden MJ; Horner SM
J Biol Chem; 2019 Sep; 294(39):14231-14240. PubMed ID: 31375559
[TBL] [Abstract][Full Text] [Related]
28. The tyrosine kinase c-Src enhances RIG-I (retinoic acid-inducible gene I)-elicited antiviral signaling.
Johnsen IB; Nguyen TT; Bergstroem B; Fitzgerald KA; Anthonsen MW
J Biol Chem; 2009 Jul; 284(28):19122-31. PubMed ID: 19419966
[TBL] [Abstract][Full Text] [Related]
29. Induction of IRF-3 and IRF-7 phosphorylation following activation of the RIG-I pathway.
Paz S; Sun Q; Nakhaei P; Romieu-Mourez R; Goubau D; Julkunen I; Lin R; Hiscott J
Cell Mol Biol (Noisy-le-grand); 2006 May; 52(1):17-28. PubMed ID: 16914100
[TBL] [Abstract][Full Text] [Related]
30. Proteomic profiling of the TRAF3 interactome network reveals a new role for the ER-to-Golgi transport compartments in innate immunity.
van Zuylen WJ; Doyon P; Clément JF; Khan KA; D'Ambrosio LM; Dô F; St-Amant-Verret M; Wissanji T; Emery G; Gingras AC; Meloche S; Servant MJ
PLoS Pathog; 2012; 8(7):e1002747. PubMed ID: 22792062
[TBL] [Abstract][Full Text] [Related]
31. Single amino acid substitutions confer the antiviral activity of the TRAF3 adaptor protein onto TRAF5.
Zhang P; Reichardt A; Liang H; Aliyari R; Cheng D; Wang Y; Xu F; Cheng G; Liu Y
Sci Signal; 2012 Nov; 5(250):ra81. PubMed ID: 23150880
[TBL] [Abstract][Full Text] [Related]
32. Lysine 63-linked TANK-binding kinase 1 ubiquitination by mindbomb E3 ubiquitin protein ligase 2 is mediated by the mitochondrial antiviral signaling protein.
Ye JS; Kim N; Lee KJ; Nam YR; Lee U; Joo CH
J Virol; 2014 Nov; 88(21):12765-76. PubMed ID: 25142606
[TBL] [Abstract][Full Text] [Related]
33. Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets.
Yang Y; Ye F; Zhu N; Wang W; Deng Y; Zhao Z; Tan W
Sci Rep; 2015 Dec; 5():17554. PubMed ID: 26631542
[TBL] [Abstract][Full Text] [Related]
34. SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING signaling pathways.
Han L; Zhuang MW; Deng J; Zheng Y; Zhang J; Nan ML; Zhang XJ; Gao C; Wang PH
J Med Virol; 2021 Sep; 93(9):5376-5389. PubMed ID: 33913550
[TBL] [Abstract][Full Text] [Related]
35. The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response.
Friedman CS; O'Donnell MA; Legarda-Addison D; Ng A; Cárdenas WB; Yount JS; Moran TM; Basler CF; Komuro A; Horvath CM; Xavier R; Ting AT
EMBO Rep; 2008 Sep; 9(9):930-6. PubMed ID: 18636086
[TBL] [Abstract][Full Text] [Related]
36. Phosphatidylinositol-3-kinase and Akt are required for RIG-I-mediated anti-viral signalling through cross-talk with IPS-1.
Yeon SH; Song MJ; Kang HR; Lee JY
Immunology; 2015 Feb; 144(2):312-20. PubMed ID: 25158146
[TBL] [Abstract][Full Text] [Related]
37. Mechanism of inhibiting type I interferon induction by hepatitis B virus X protein.
Jiang J; Tang H
Protein Cell; 2010 Dec; 1(12):1106-17. PubMed ID: 21213104
[TBL] [Abstract][Full Text] [Related]
38. Ndfip1 negatively regulates RIG-I-dependent immune signaling by enhancing E3 ligase Smurf1-mediated MAVS degradation.
Wang Y; Tong X; Ye X
J Immunol; 2012 Dec; 189(11):5304-13. PubMed ID: 23087404
[TBL] [Abstract][Full Text] [Related]
39. TRIM11 negatively regulates IFNβ production and antiviral activity by targeting TBK1.
Lee Y; Song B; Park C; Kwon KS
PLoS One; 2013; 8(5):e63255. PubMed ID: 23675467
[TBL] [Abstract][Full Text] [Related]
40. TRAF3IP3 mediates the recruitment of TRAF3 to MAVS for antiviral innate immunity.
Zhu W; Li J; Zhang R; Cai Y; Wang C; Qi S; Chen S; Liang X; Qi N; Hou F
EMBO J; 2019 Sep; 38(18):e102075. PubMed ID: 31390091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
